Why I’m Not Chasing AMC’s Odyssey
Here’s the latest on our Ocular Therapeutix trading strategy, a planned purchase for today and some additional portfolio news.
Our Ocular Call Is Set to Expire as Market Struggles
We’re a bit handcuffed when it comes to making moves in our small-cap portfolio.
After a Tough Run for the $10K Portfolio, Time to Get Back in the Win Column
From up 32% to slightly underwater, here’s what recently went awry — and what’s next.
Two Charts, Three Buys and a Fourth Attempt
Planet Labs and Evolv both sit at critical technical areas. Here’s my trading plan.
Adding to 2 Names as We Hope Third Time’s a Charm on a Sale
A third attempt to trim Rackspace is on deck while we make a couple of buys and prepare for a Friday option expiration.
Selling Rackspace, Buying Ondas Ahead of Earnings Season
We’re using the season before the unofficial start of earnings season to adjust some semi-rancid positions.
Who the Heck Is Inseego? We’re Buying the Small-Cap 5G Firm
We’re taking a closer look at the defense contractor following a recent peak.
How David Tepper Is Positioning for What Lies Ahead
The hedge fund manager’s approach aligns with my current strategy.
Selling Rackspace After Guidance Cut Drives a Change of Strategy
The firm cut guidance and then announced a pivot, so we’re going to trim the position before entering the red.
I Don’t Know About You, But I’m Feeling These 22 Biotech Stocks
The market is in a transitional phase as we await earnings.